Title | Pioglitazone Therapy of PAX8-PPARγ Fusion Protein Thyroid Carcinoma. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Giordano TJ, Haugen B, Sherman SI, Shah MH, Caoili EM, Koenig RJ |
Journal | J Clin Endocrinol Metab |
Date Published | 2018 Jan 24 |
ISSN | 1945-7197 |
Abstract | Context: A subset of thyroid carcinomas expresses an oncogenic PAX8-PPARγ fusion protein (PPFP). The PPARγ/PPFP ligand pioglitazone is highly therapeutic in a transgenic mouse model of PPFP thyroid carcinoma, but whether pioglitazone is therapeutic in patients with PPFP thyroid carcinoma is unknown. Case Description: Tumor blocks from forty patients with progressive thyroid cancer despite standard of care therapy were screened for PPFP, and the tumor from only one patient (2.5%) was positive. The patient had a 6.0 cm acetabular soft tissue metastasis from Hurthle cell carcinoma causing severe pain on weight bearing, and a serum thyroglobulin level of 1974 ng/mL. After 24 weeks of therapy with pioglitazone, the metastasis was 3.9 cm, the thyroglobulin was 49.4 ng/mL and the patient was pain free. Thirteen months after discontinuing pioglitazone, the metastasis was 3.6 cm, the thyroglobulin was 4.7 ng/mL and the patient remained pain free. Conclusions: Pioglitazone may be therapeutic in patients with PPFP thyroid cancer. However, thyroid cancers that are progressive despite standard of care therapy appear to only rarely express PPFP. |
DOI | 10.1210/jc.2017-02533 |
Alternate Journal | J. Clin. Endocrinol. Metab. |
PubMed ID | 29373711 |
Submitted by kej2006 on June 6, 2018 - 4:13pm